UNITY Biotechnology, Inc. Reports First Quarter 2025 Financial Results and Business Updates
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Apr 22 2025
0mins
Source: Newsfilter
Financial Results: UNITY Biotechnology reported a net loss of $7.3 million for Q1 2025, with cash reserves sufficient to fund operations until late 2025; research and development expenses decreased due to nearing completion of the Phase 2 ASPIRE study for diabetic macular edema (DME).
Clinical Study Update: The Phase 2b ASPIRE study showed that UBX1325 treatment led to vision improvements in DME patients, although it did not meet the primary endpoint of non-inferiority to aflibercept at weeks 20 and 24; full 36-week data is expected in Q2 2025.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
